



**Dr. Reddy's Laboratories Ltd.**

8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: [mail@drreddys.com](mailto:mail@drreddys.com)

Web: [www.drreddys.com](http://www.drreddys.com)

December 12, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

**Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that the United States Food & Drug Administration (USFDA) today completed a GMP and a Pre-Approval Inspection (PAI) at our formulations facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh. The inspection was conducted from 4<sup>th</sup> December to 12<sup>th</sup> December, 2025. We have been issued a Form 483 with 5 observations, which we will address within the stipulated timeline.

This is for your information and record.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*